Cash-pay telehealth generally does not bill health plans, so the platform figure is the entire figure. Moving the same prescription onto insurance swaps that single number for three variables: the deductible, the formulary tier, and whatever the plan’s prior authorization rules permit. Coverage beats cash when it exists, and for several of these categories it frequently does not.

By Dr. Jason Itri, MD, PhD

These are two different purchases, not two prices for one item

A subscription platform sells a bundle: an asynchronous clinical review, a prescription, a dispensed product, and delivery, all on one recurring charge. A health plan pays for a drug on its formulary, dispensed by a network pharmacy, prescribed by a clinician the member finds separately. The bundle is the reason the cash route can quote one clean figure.

That bundling is also why a straight comparison misleads. Set against an insured route, the cash figure includes clinical time that a plan would bill separately as an office visit, and excludes the deductible spending that an insured patient may already have absorbed elsewhere in the year.

What the covered route actually charges

Marketplace plans have to include prescription drugs among the essential health benefits, but the benchmark plan and the formulary decide which molecules are on the list and at what tier. A drug on tier one behaves like a small fixed copay. A drug on a specialty tier behaves like coinsurance, a percentage of a price the member never sees quoted.

Before either applies, the deductible has to be met on plans that put pharmacy spending behind it. In January the covered route can cost more than the cash route for the same molecule, and by autumn the same plan can cost far less. Any comparison made in one month is a snapshot of a moving position.

Prior authorization sits on top. It is the plan’s requirement that the prescriber justify the drug before it is paid for, and research in dermatology has documented the delay and administrative load that requirement adds to specialist care. Step therapy adds a further condition, requiring a cheaper alternative to fail first.

Dimension	Cash telehealth route	Health plan route
Headline number	One recurring charge, published up front	Copay or coinsurance, knowable only after the formulary check
Clinical review	Included in the subscription	Billed as a separate visit, subject to its own cost sharing
Approval friction	Intake questionnaire, decision in days	Prior authorization and step therapy on many drugs
Deductible exposure	None, nothing counts toward a deductible	Pharmacy spending may sit behind the deductible
Category exclusions	Not applicable, everything is self-paid	Weight loss, hair, and sexual health are commonly excluded
Recourse if denied	Change product or stop	Internal appeal, then external review
Annual predictability	High, until a dose or term change	Low early in the plan year, higher later

Where coverage tends to fail in these specific categories

Weight management is the sharpest case. Reimbursement for obesity pharmacotherapy in the United States has been constrained for decades, and commercial coverage of approved anti-obesity medication still varies plan by plan and employer by employer. Where an employer has bought the benefit, the covered route usually wins outright. Where it has not, cash is the only route.

Because coverage turns on the employer and the diagnosis, several telehealth providers now address the benefits question directly on their sites. HealthRX, for instance, publishes guidance on GLP-1 insurance coverage, Ro and Hims and Hers explain when a plan may pay for an approved anti-obesity drug, and Henry Meds leans toward the cash route from the start. None of those pages settles what a specific plan will pay, but reading them shows how differently each seller expects coverage to land.

Hair loss and sexual health are frequently written out of drug benefits as lifestyle or cosmetic treatment, or capped with quantity limits that cover fewer tablets than a subscription supplies. Mental health prescribing is generally covered, though the visits that support it carry their own cost sharing. Skin care splits, with medical dermatology covered and cosmetic formulations not.

Comparison pages published by competing cash programs are useful for mapping which categories they treat as coverable, and a Hims cost breakdown at formblends.com is one example of the genre, as are the pricing explainers kept by Ro, Found, and Noom. Treat any of them as a description of the seller’s own structure rather than a neutral reading of what a given plan will pay.

Medicare and Medicaid follow separate rules

Medicare drug coverage runs through Part D plans, each with a formulary and its own cost sharing, and a longstanding statutory exclusion has kept agents prescribed purely for weight loss outside that benefit. The same molecule can be covered when it is prescribed for a different indication the program does recognize, which is why coverage questions in this category turn on the diagnosis rather than the drug.

Medicaid drug benefits are set state by state, with their own preferred drug lists. In both programs, manufacturer copay cards are unavailable to beneficiaries under federal anti-kickback rules, so the savings routes that work for commercially insured patients do not transfer.

Making the covered route work when it is available

A denial is the start of a process, not the end of one. Plans run an internal appeal first, and if that fails an independent external review can overturn the decision, with the exact route depending on the state and the plan type. Formulary exception requests are the specific tool where a drug is absent from the list rather than merely restricted.

Two smaller mechanics matter for anyone straddling both routes. Health savings and flexible spending funds can be applied to eligible medical expenses whichever route supplies the drug, subject to plan substantiation. And a superbill from a cash provider is worth asking about at sign-up, since some plans will apply out-of-network reimbursement to a documented consult even when they will not touch the medication.

Frequently asked questions

Will a cash telehealth platform submit a claim to insurance?

Generally not for medication. The model depends on skipping claims processing, which is part of how the price stays fixed and published. Some platforms provide an itemized receipt on request, which a member can submit for out-of-network consideration. Whether anything is reimbursed is decided by the plan, not the platform.

Does money spent on a cash subscription count toward the deductible?

No. Spending outside the plan does not accumulate toward a deductible or an out-of-pocket maximum unless a claim is filed and accepted. That is a real cost of the cash route for anyone with a plan that would eventually cover the same treatment, and it is invisible in any monthly comparison.

If a plan denies the drug, is cash the only remaining option?

Not immediately. An internal appeal, followed by external review where available, resolves a meaningful share of denials, and a formulary exception can add a drug that was never listed. Those routes take weeks. Paying cash while an appeal runs is common, and the cash spending is rarely recoverable afterward.

Is the covered route always cheaper when coverage exists?

Usually, though not on day one of a plan year with an unmet pharmacy deductible, and not always on a specialty tier where coinsurance is a percentage of a high negotiated price. The reliable comparison is annual rather than monthly, because the covered route front-loads cost and the cash route spreads it evenly.

Sources

• HealthCare.gov, Getting prescription medications. https://www.healthcare.gov/using-marketplace-coverage/prescription-medications/
• HealthCare.gov, Find out what Marketplace health insurance plans cover. https://www.healthcare.gov/coverage/what-marketplace-plans-cover/
• HealthCare.gov, Prior authorization glossary entry. https://www.healthcare.gov/glossary/prior-authorization/
• HealthCare.gov, Formulary glossary entry. https://www.healthcare.gov/glossary/formulary/
• HealthCare.gov, Internal appeals. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
• HealthCare.gov, External Review. https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
• CMS, Information on Essential Health Benefits Benchmark Plans. https://www.cms.gov/marketplace/resources/data/essential-health-benefits
• Medicare, What’s Medicare drug coverage (Part D)? https://www.medicare.gov/drug-coverage-part-d
• CMS, Prescription Drug Coverage General Information. https://www.cms.gov/medicare/coverage/prescription-drug-coverage
• The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA. https://pubmed.ncbi.nlm.nih.gov/25686799/
• Evaluating the effect of prior authorizations in patients with complex dermatologic conditions. https://pubmed.ncbi.nlm.nih.gov/32622138/
• DailyMed, Wegovy prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY